Investor Service Announcement no. 2/2010

To: NASDAQ OMX Copenhagen Hørsholm, Denmark, May 7, 2010


LifeCycle Pharma A/S to Host Conference Call Announcing
Interim Report for 1st Quarter 2010 - results from January 1 to March 31, 2010

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 1st Quarter
2010 on Wednesday May 12, 2010 after 05:00 PM. LCP's Executive Management will
host an accompanying conference call to discuss the financial results on
Wednesday May 12, 2010 at 05:30 PM CET (Denmark); 04:30 GMT (London), 11:30 AM
ET (New York), 08:30 AM PT (San Francisco).

To access the live conference call, please dial one of the following numbers:
+45 32 71 47 75 (Denmark) Toll
+1 212 444 0481 (USA) Toll
+44 (0)20 7136 2051 (UK) Toll

An call audio replay of the conference will be available on www.lcpharma.com
from Thursday, May 13, 2010 at 18:00 CET (Denmark); 17:00 GMT (London), 12:00 PM
ET (New York), 09:00 AM PT (San Francisco), through Friday, June 11, 2010 by
dialing +45 32 71 09 13 (DK), +44 (0) 20 7111 1244 (UK) or +1 347 366 9565 (US),
and entering access code 2534991#.

For more information, please contact:
Dr. William J. Polvino or Peter Schøtt Knudsen
President & Chief Executive Officer Head of Investor Relations
Phone: + 45 7033 3300 Phone: + 45 2055 3817
Email: [email protected] Email: [email protected]


About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at low-scale
up costs - not only for a broad spectrum of drugs already on the market, but
also for new chemical entities. LCP has a cholesterol-lowering product,
Fenoglide®, currently on the U.S. market and a diversified near- and medium-term
pipeline with four product candidates in clinical trials and a number of
projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen
under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.

12052010 - lifecycle pharma to host interim report q1 2010 call .pdf